2022 Presenting Companies
Curocell Inc. is CAR-T Cell Therapy specialized company based in Korea.
We are successfully carrying out our Phase Ⅱ Clinical Trial with CRC01 (Anbalcabtagene autoleucel)-OVIS™ technology applied CD19 Targeting CAR-T Cell Therapy in Korea. We have recently begun construction of our GMP manufacturing site to be prepared for commercial production of our innovative CAR-T Cell Therapy. Our mission is to provide patients with better lives with innovative technologies. Our OVIS™ technology is applicable to various types of immune cell therapy and has already been proven to be effective in overcoming immune suppression.
We’d like to share our technology worldwide, giving out a hand to patients anywhere in the world.